Recent Phase 1b study results for its Crohn's disease treatment showed a favorable safety profile with no serious adverse events. :
It was also recognized as a top stock for day trading due to high relative volume. Value-Oriented Biotech Picks best biotech stocks to buy under $10
The primary catalyst is upcoming clinical data for ulcerative colitis, expected in the second half of 2027. Recent Phase 1b study results for its Crohn's
Searching for biotech stocks under $10 reveals several companies with strong analyst backing and significant upcoming catalysts. As of late 2025 and early 2026, the following stocks are frequently highlighted by financial experts for their growth potential: Top Rated Biotech Stocks Under $10 : Searching for biotech stocks under $10 reveals several
: Highlighted for strengthening its global reach through strategic deals, such as the one with Kyowa Kirin.
According to data from WallStreetZen , several lower-priced biotechs show favorable Price-to-Earnings (P/E) ratios compared to industry peers as of early 2026: BioCryst Pharmaceuticals AUPH Aurinia Pharmaceuticals TBPH Theravance Biopharma PBYI Puma Biotechnology
Consistently featured in lists of best biotechs under $10 and is noted for its Cancer BioShield platform targeting lymphopenia.